Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl-b Inhibitors-Reference-Cited by-同舟云学术

Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl-b Inhibitors

Published:2024-01-16 Issue:2 Volume:67 Page:1500-1512
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Mfuh Adelphe M.¹^ORCID,Boerth Jeffrey A.¹^ORCID,Bommakanti Gayathri²,Chan Christina³,Chinn Alex J.¹,Code Erin²,Fricke Patrick J.¹,Giblin Kathryn A.³^ORCID,Gohlke Andrea⁴,Hansel Catherine⁴,Hariparsad Niresh¹^ORCID,Hughes Samantha J.³,Jin Meizhong¹,Kantae Vasudev⁴^ORCID,Kavanagh Stefan L.⁴,Lamb Michelle L.¹^ORCID,Lane Jordan⁴,Moore Rachel⁴,Puri Taranee¹,Quinn Taylor R.¹,Reddy Iswarya²,Robb Graeme R.³^ORCID,Robbins Kevin J.¹,Gancedo Rodrigo Miguel⁴⁵^ORCID,Schimpl Marianne³^ORCID,Singh Baljinder¹^ORCID,Singh Meha¹,Tang Haoran⁴,Thomson Clare³^ORCID,Walsh Jarrod J.⁴,Ware Jamie⁴,Watson Iain D. G.¹^ORCID,Ye Min-Wei²,Wrigley Gail L.³,Zhang Andrew X.²^ORCID,Zhang Yun¹,Grimster Neil P.¹^ORCID

Affiliation:

1. Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States

2. Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States

3. Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.

4. Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K.

5. Isomorphic Laboratories, 280 Bishopsgate, London EC2M 4RB, U.K.

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c02083

Reference43 articles.

1. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors